Standard analgesic practices in the treatment of central and peripheral neuropathic pain syndromes (including opioids, tricyclic antidepressants, anticonvulsants, NMDA receptor antagonists, and other ion channel antagonists) have thus far provided inadequate pain relief.
Our studies investigate pain relief in peripheral and central neuropathic pain states by examining how novel drugs effect different pain mechanisms. For example, recent basic and clinical research with new drugs opens the possibility for new treatments.
If you are interested in participating or learning more about our research, please contact us.
Sponsors of Our Research Have Included:
- National Institute of Neurological Diseases and Stroke (National Institutes of Health)
- Christopher Reeve Foundation
- Mike Utley Foundation
- Paralyzed Veterans of America
- Lilly Research Laboratories
- Endo Pharmaceuticals, Inc.
- Pfizer, Inc.
- Johnson & Johnson Subsidiaries
- AstraZeneca
- Schwarz Pharma
- Cogentix, Inc.
- Gedeon Richter Ltd
